FK 749 is a new parenteral cephalosporin derivative which is more active against various gram-negative bacilli, including the opportunistic pathogens such as Enterobacter, Citrobacter species, and Serratia marcescens, than cephalosporins and cephamycins such as cefotiam, cefamandole, cefuroxime, cefotaxime, and cefmetazole. FK 749 was especially active against gram-negative organisms resistant to these related antibiotics. FK 749 was more potent in bactericidal activity than the other antibiotics, and the activity was clearly enhanced in the presence of 90% defibrinated rabbit blood. The therapeutic effect of subcutaneously injected FK 749 in mice infected with various gram-negative bacilli was far superior to that of cefotiam, cefamandole, cefuroxime, and cefmetazole and was almost the same as that of cefmetazole in mice infected with Staphylococcus aureus and that of ticarcillin in mice infected with Pseudomonas aeruginosa. FK 749 has, in general, nearly the same in vitro and in vivo antibacterial activities as cefotaxime. The former had more potent bactericidal activity in the presence of the blood than the latter and showed more excellent therapeutic effect than cefotaxime against infections caused by large inoculum sizes.
The cephalosporins cefazolin (4) and ceftezole (5) resulted from our drug development program. In the continuing search for new cephalosporins with even greater antibacterial activity against a wide variety of gram-positive and gram-negative organisms, including the opportunistic pathogens, FK 749, a distinctive new parenteral cephalosporin derivative, was recently developed (Fig. 1) . FK 749 has been proven to exert excellent antibacterial activity in vitro. In animal experiments with FK 749, it was also found that the drug is more (potently) active, especially against various gram-negative bacilli including the opportunistic pathogens, than other known cephalosporins and cephamycins tested. Preliminary evaluations suggest that FK 749 will be a valuable antibiotic for a wide range of clinical applications. We report here the results.
MATERIALS AND METHODS Antibiotics. The antibiotics used in this study in (T 1220 ; Toyama Chemical Co., Ltd., Toyama, Japan), and gentamicin (Schering Corp., Bloomfield, N.J.).
Bacterial strains. Standard strains from the culture collection of this laboratory were used in the study. Clinical isolates of various species of bacteria were obtained from several hospitals in Japan.
Antibiotic susceptibility. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method using heart infusion agar (HI agar, Difco Laboratories, Detroit, Mich.), unless otherwise specified. For testing Haemophilus influenzae, Neisseria species, and streptococcal species, except Streptococcus faecalis, the medium was supplemented with 5% defibrinated horse blood. The inoculum was grown in Trypticase soy broth (BBL Microbiology Systems, Cockeysville, Md.) overnight at 37°C. The broth was supplemented with 10% Fildes enrichment (Difco) for H. influenzae and with 5% defibrinated horse blood for Neisseria species and streptococcal species. An overnight broth culture and decimal dilutions thereof were streaked or spot-inoculated onto the agar media containing graded concentrations of the test antibiotics. MICs were read after incubation at 37°C for 20 h. For testing anaerobic bacteria, incubation was performed by the GasPak method (BBL) at 37°C; GAM broth (Nissui, Tokyo) and GAM agar (Nissui) were used for the preculture and test culture, respectively. jig/ml, respectively, i.e., about the same as those of cefuroxime, cefotaxime, and cefmetazole, and were slightly higher than those of cefotiam and cefamandole. However, the 80% inhibitory concentration of FK 749 against the test strains of S. pyogenes, i.e., _0.025 ,ug/ml, was about the same as those of cefuroxime and cefotaxime, but was much lower than those of the other related antibiotics. The 80% inhibitory concentrations of FK 749 against the test strains of E. coli, Klebsiella pneumoniae, Proteus mirabilis and indole-positive Proteus species (except Proteus morganii), and Serratia marcescens were much lower, i.e., '0.025 to 1.56 jig/ml, than those of the other drugs tested. On the other hand, against P. morganii, Citrobacter freundii, Enterobacter species, H. influenzae, and Bacteroides fragilis, the 50% inhibitory concentrations of FK 749 ranged from '0.025 to 1.56 ,ug/ ml, and the 80% inhibitory concentrations (_0.025 to 50 ,tg/ml) were almost the same as those of cefotaxime. However, the antibacterial activity of the drug was far greater than those of the other drugs tested. FK 749 inhibited the Bactericidal activity. The effect of the test antibiotics on the viable cell count of E. coli 5 was investigated with inocula of 106 and 10' CFU/ml in both HI broth and 90% defibrinated rabbit blood.
Low inoculum size (10' CFU/ml). Figure   2A shows the changes in viable cell count of E. coli 5 inoculated in HI broth containing 5,ug of the test antibiotics per ml. The bactericidal activity of FK 749 and cefotaxime at 5 jig/ml was greater than that of the other antibiotics tested, and the viable cell counts were decreased markedly in 1 h by both drugs. The other drugs showed almost the same bactericidal activity as that of FK 749 when tests were carried out for 3 h.
In the presence of 90% defibrinated rabbit blood (Fig. 2B) , the bactericidal activity of FK 749 did not decrease and, in fact, was superior to its activity in HI broth. The activity of cefotaxime, however, decreased in the presence of blood. The activity of cefuroxime was almost the same in the presence of blood as that of FK 749 in 3-h incubations.
Heavy inoculum size (10 CFU/ml). The bactericidal activities of the test antibiotics were compared as above except that a heavy inoculum (10' CFU/ml) was used. Figure 3A shows that the bactericidal activity of the antibiotics except cefamandole at 10' CFU/ml was nearly the same as that at 106 CFU/ml when HI broth was used as the culture medium. In the presence of blood, most of the bactericidal activity of the antibiotics except FK 749 was lost; however, that of FK 749 was retained and was, in fact, enhanced (Fig. 3B) with various species of organisms was compared with that of the other antibiotics as described under Materials and Methods. Table 6 shows the ED50 values in mice given the test antibiotics subcutaneously 1 h after challenge. The ED50 values of FK 749 for S. aureus 47 infections were 1.44 mg/kg and were about the same as those of cefotaxime and cefamandole. The therapeutic effect of FK 749 was slightly inferior to that of cefamandole and cefuroxime but was superior to that of cefotiam. The therapeutic effect of FK 749 on infections due to E. coli, K. pneumoniae, indole-negative and -positive Proteus species, and Enterobacter cloacae 63 was almost the same as that of cefotaxime and was by far superior to that of the other test drugs. In contrast, FK 749 was more effective than cefotaxine against infections due to C. freundii 13 and S. marcescens 32 and was equal to ticarcillin and piperacillin in effect against infections due to P. aeruginosa 93.
Influence of challenge dose on the protective effect ofFK 749 and cefotaxime against infections in mice. The therapeutic effect of FK 749 was compared with that of cefotaxime against all infections due to various challenge doses of E. coli, P. vulgaris, and S. marcescens. As shown in Table 7 , the therapeutic effect of FK 749 was nearly the same as that of cefotaxime against all infections due to the challenge size of 1 minimum lethal dose (MLD) of the test organisms. FK 749, however, was more effective than cefotaxime against all infections due to large challenge doses (100 or 10,000 MLD) of the test organisms. Specifically, ED50 values of FK 749 were increased by a factor of '9 to 85 when the challenge dose was 100 or 10,000 MLD rather than 1 MLD. Similar results were obtained in the case of cefotaxime using the same organisms, but the extent of the decrease of ED50 values of The antibiotic cefotaximne, which is similar to FK 749 in chemical structure (aminothiazole ring at the 7-position), showed antibacterial activity very similar to that of FK 749. The therapeutic effect of FK 749 in mice infected with a small inoculum size was almost the same as that of cefotaxime. However, the therapeutic effect of cefotaxime in mice infected with a large inoculum size was significantly inferior to that of FK 749. The difference between FK 749 and cefotaxime in their in vivo effects may be explained by their bactericidal activity in the presence of 90% defibrinated blood. When a large inoculum size of 105 CFU/ml was used, the bactericidal activity of the other antibiotics including cefotaxime was clearly less than when a lower inoculum was used. The bactericidal activity of FK 749, however, did not decrease under these conditions; rather, it was enhanced. To elucidate this phenomenon, investigations on the effect of FK 749 and the other antibiotics on the bactericidal activity of phagocytes in the blood are needed.
In view of the studies described in this paper, which show FK 749 to be more potent than related antibiotics in various in vitro and in vivo tests, it is concluded that the antibiotic has considerable potential for clinical application.
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